Wednesday, June 21, 2017 9:12:42 AM
Israeli credit card firm Isracard names outgoing Teva CFO as chairman
Israel's biggest credit card company Isracard on Wednesday named Eyal Desheh, the outgoing chief financial officer of Teva Pharmaceutical Industries , as its new chairman.
Teva in April said Desheh would step down at end-June after nearly a decade in the job, the second top official to resign from the Israel-based company this year.
Isracard is a unit of Bank Hapoalim, Israel's largest lender. A new regulation requires that Hapoalim and top rival Leumi sell off their credit card units in the coming years.
Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps. Then chairman Yitzhak Peterburg replaced Vigodman on a temporary basis.
At Isracard Desheh replaces Ronen Stein, deputy CEO of Hapoalim. Under new rules, a manager at the credit card companies cannot also serve as a member of board of management at a bank.
Desheh served as deputy CFO at Teva from 1989 to 1996 before becoming CFO of Scitex and then Check Point Software Technologies. He returned as Teva's CFO in 2008 and was acting CEO from October 2013 to February 2014.
Michael McClellan has been named interim CFO at Teva, where for the last two years he was CFO of Teva's speciality medicines division. (Reporting by Tova Cohen; Editing by Steven Scheer and David Evans)
Recent TEVA News
- Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia • GlobeNewswire Inc. • 09/23/2024 05:00:00 AM
- Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia • GlobeNewswire Inc. • 09/21/2024 08:15:00 AM
- New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) • GlobeNewswire Inc. • 09/21/2024 08:10:00 AM
- Teva to Present at the Bank of America 2024 Global Healthcare Conference • GlobeNewswire Inc. • 09/11/2024 08:30:00 PM
- GameStop plunges 11% on stock offering, DJT drops post-debate, GSK fails shingles vaccine trial • IH Market News • 09/11/2024 10:25:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:40:42 AM
- Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/26/2024 09:00:00 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:06:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:09:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:06:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:02:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 07:59:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 08:06:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:00:57 AM
- Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- US Index Futures Up Ahead of Fed Decision; Oil Prices Surge Amid Middle East Tensions • IH Market News • 07/31/2024 10:01:30 AM
- Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease • Business Wire • 07/25/2024 05:30:00 AM
- Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine • Business Wire • 07/18/2024 12:30:00 PM
- Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024 • Business Wire • 07/02/2024 10:00:00 PM
- Les nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiques • Business Wire • 06/28/2024 10:34:00 PM
- Neue Daten zu AJOVY® (Fremanezumab) zur Migräneprävention stellen Behandlungspausen in Frage • Business Wire • 06/28/2024 07:41:00 PM
- New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses • Business Wire • 06/28/2024 03:30:00 PM
- Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020 • Business Wire • 06/25/2024 12:00:00 PM
- Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States • Business Wire • 06/24/2024 01:50:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM